Idebenone: A review of its use in mild to moderate Alzheimer's disease

CNS Drugs

Volumn 9, Issue 5, 1998, Pages 403-419

  Adkins, Julie C ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; FLUVOXAMINE; IDEBENONE; LITHIUM; NORTRIPTYLINE;

ALZHEIMER DISEASE; ANGINA PECTORIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HEARTBURN; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SLEEP DISORDER;

EID: 0031748811     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809050-00006     Document Type: Review

References (70)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 133-55
2. Herrmann N, Lanctôt KL, Naranjo CA. Behavioural disorders in demented elderly patients: current issues in pharmacotherapy. CNS Drugs 1996 Oct; 6: 280-300
3. Class CA, Schneider L, Farlow MR. Optimal management of behavioural disorders associated with dementia. Drugs Aging 1997 Feb; 10:95-106
4. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997 May; 154 Suppl.: 1-39
5. Haxby JV, Grady CL, Duara R, et al. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. Arch Neurol 1986 Sep; 43: 882-5
6. Blass JP. Pathophysiology of the Alzheimer's syndrome. Neurology 1993; 43 Suppl. 4: S25-S38
7. Mielke R, Herholz K, Grond M, et al. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia 1994; 5: 36-41
8. Szelies B, Mielke K, Grond M, et al. P300 in Alzheimer's disease: relationships to dementia severity and glucose metabolism. J Neurol Sci 1995; 130: 77-81
9. Zs-Nagy I. A proposal for reconsideration of the role of oxygen free radicals in cell differentiation and aging. Ann N Y Acad Sci 1992; 673: 142-8
10. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38: 357-66
11. Benesová O. Neuropathobiology of senile dementia and mechanism of action of nootropic drugs. Drugs Aging 1994 Apr; 4: 285-303
12. Smith MA, Sayre LM, Monnier VM, et al. Radical ageing in Alzheimer's disease. Trends Neurosci 1995; 18 (4): 172-6
13. Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 1995; 56 (4): 1151-71
14. Zs-Nagy I, Floyd RA. ESK spin trapping studies on the OH(.) free radical reactions of idebenone. Arch Gerontol Geriatr 1990; 11 (3): 215-31
15. Suno M, Nagaoka A. Inhibition of brain mitochondrial swelling by idebenone. Arch Gerontol Geriatr 1989 May; 8: 299-305
16. Suno M, Nagaoka A. Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Commun 1984 Dec 28; 125: 1046-52
17. Sugiyama Y, Fugita T, Matsumoto M, et al. Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J Pharmacobiodyn 1985 Dec; 8: 1006-17
18. Nagai Y, Yoshida K, Narumi S, et al. Brain distribution of idebenone and its effect on local cerebral glucose utilization in rats. Arch Gerontol Geriatr 1989 May; 8: 257-72
19. Nagaoka A, Suno M, Shibota M, et al. Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia. Arch Gerontol Geriatr 1989 May; 8: 193-202
20. Sugiyama Y, Fujita T. Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Lett 1985 May 6; 184: 48-51
21. Miyamoto M, Murphy TH, Schnaar RL, et al. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther 1989 Sep; 250: 1132-40
22. Miyamoto M, Coyle JT. Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins. Exp Neurol 1990 Apr; 108: 38-45
23. Hayako H, Hirai K, Kato K, et al. Idebenone attenuates amyloid β-peptide-induced cell death in rat hippocampal neuronal cell cultures [abstract]. Jpn J Pharmacol 1997; 73 Suppl. I: 245P
24. Nitta A, Hasegawa T, Nabeshima T. Oral administration of idebenone, a stimulator of NGF synthesis, recovers reduced NGF content in aged rat brain. Neurosci Lett 1993 Dec 12; 163: 219-22
25. Nabeshima T, Nitta A, Fuji K, et al. Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats. Gerontology 1994; 40 Suppl. 2: 46-56
26. Nitta A, Murakami Y, Furukawa Y, et al. Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol 1994 Apr; 349: 401-7
27. Yamada K, Nitta A, Hasegawa T, et al. Orally active NGF synthesis stimulalors: potential therapeutic agents in Alzheimer's disease. Behav Brain Res 1997 Feb; 83: 117-22
28. Kakihana M, Yamazaki N, Nagaoka A. Effects of idebenone on the levels of acetylcholine, choline, free fatty acids, and energy metabolites in the brains of rats with cerebral ischemia. Arch Gerontol Geriatr 1989 May; 8: 247-56
29. Yamamoto T, Ohno M, Yatsugi S-i, et al. Nootropic candidates inhibit head-twitches induced by mescaline in mice. Jpn J Pharmacol 1992 Jul; 59: 419-21
30. 14C]catecholamine formation by cultured bovine adrenal chromaffin cells. Biochem Pharmacol 1991 Jul 25; 42: 951-4
31. 2+ channels in cultured adrenal chromaffin cells. Jpn J Pharmacol 1991 Dec; 57: 553-8
32. Scavini C, Rozza A, Lanza E, et al. Effect of idebenone on in vivo serotonin release and serotonergic receptors in young and aged rats. Eur Neuropsychopharmacol 1996 May; 6: 95-102
33. Ishihara K, Katsuki H, Sugimura M, et al. Idebenone and vinpocetine augment long-term potentiation in hippocampal slices in the guinea pig. Neuropharmacology 1989 Jun; 28: 569-73
34. Yamazaki N, Kiyota Y, Take Y, et al. Effects of idebenone on memory impairment induced in ischemic and embolization models of cerebrovascular disturbance in rats. Arch Gerontol Geriatr 1989 May; 8: 213-24
35. Yamazaki N, Take Y, Nagaoka A, et al. Beneficial effects of idebenone (CV-2619) on cerebral ischemia-induced amnesia in rats. Jpn J Pharmacol 1984; 36: 349-56
36. Yamazaki N, Nomura M, Nagaoka A, et al. Idebenone improves learning and memory impairment induced by cholinergic or serotonergic dysfunction in rats. Arch Gerontol Geriatr 1989 May; 8: 225-39
37. Greenamayre JT. The role of glutamate in neurotransmission and in neurologic disease. Arch Neurol 1986 Oct; 43: 1058-63
38. Parnetti L. Senin U. Mecocci P. Cognitive enhancement therapy for Alzheimer's disease, the way forward. Drugs 1997 May; 53: 752-68
39. Honegger P, Lenoir D. Nerve growth factor (NGF) stimulation of cholinergic telencephalic neurons in aggregating cell cultures. Dev Brain Res 1982; 3: 229-38
40. Gnahn H, Hefti F. Heumann R, et al. NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? Dev Brain Res 1983; 9: 45-52
41. Kowall NW, Flint Beal M. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease. Ann Neurol 1988; 23: 105-14
42. Maeda K, Kawata E, Sakai K, et al. Effects of putative cognitive function-enhancing drugs and dopaminergic agents on somatostatin and neuropeptide Y in rat brain. Eur J Pharmacol 1993 Mar 23; 233: 227-35
43. Boni J, Maugeri A, Zingali G, et al. Steady-state pharmacokinetics at idebenone in healthy volunteers. Archives Gerontol Geriatr 1992 Nov-Dec; 15: 197-205
44. Hermann R, Blume H, Fieger-Büschges H. Study on pharmacokinetics and bioavailability of idebenone after double-blind, single-dose administration of five different dosages (30 mg, 60 mg, 90 mg, 120 mg, 180 mg) to 20 healthy volunteers. Takeda (Japan). EC067; 1995 (Data on file)
45. Lenz T, Blume H, Fieger-Büschges H, et al. Study on pharmacokinetics and bioavailability of idebenone after single-and multiple-dose administration to 24 elderly volunteers. Takeda (Japan). 1995/1996. Report no.: EC069. (Data on file)
46. Takamitsu Y, Higashi S. Clinical phase I study of idebenone (CV-2619) [in Japanese]. Rinsho Iyaku 1985; 1: 11-24
47. Lenz T, Blume H, Fieger-Büschges H, et al. Internal report EC068. Takeda (Japan), 1995 (Data on file)
48. Inagaki Y, Matsuhara M. An investigation into the pharmacokinetics of repetitive administration of CV-2619 tablets in treatment of geriatric patients with cerebrovascular disorders [in Japanese]. Kiso to Rinsho 1985 Mar; 19 (3): 296-306
49. Miyazaki M, Hattori M. An investigation of the pharmacokinetics of CV-2619 (idebenone) tablets in patients with cerehrovascular disorders (in Japanese). Kiso to Rinsho 1986; 20 (12): 276-80
50. Coto V, Oliviero U, Sorrentino P, et al. Steady-state pharmacokineties of idebenone in patients with moderate renal impairment. Arch Gerontol Geriatr 1992 Nov-Dec; 15: 215-23
51. Coto V, Oliviero U, Sorrentino P, et al. Steady-state pharmacokinetics of idebenone in patients with moderate hepatic impairment. Arch Gerontol Geriatr 1992 Nov-Dec; 15: 207-14
52. Torii H, Yoshida K, Kobayashi T, et al. Disposition of idebenone (CV-2619), a new cerebral metabolism improving agent, in rats and dogs. J Pharmacobiodyn 1985 Jun; 8: 457-67
53. Zs-Nagy I. Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone - a review. Arch Gerontol Geriatr 1990 Nov-Dec; 11: 177-86
54. Takeda Chemical Industries, Ltd. Clinical expert report on idebenone. Takeda (Japan). Jun 1996. (Data on file)
55. 14C (Protocol no. M90-441). Takeda (Japan), 1990. Report no.: EC052. (Data on file)
56. Barkworth MF, Dyde CJ, Johnson KI, et al. An early phase I study to determine the tolerance, safety and pharmacokinetics of idebenone following multiple oral doses. Arzneimittel Forschung 1985; 35: 1704-7
57. Rost KL, Wierich W, Hadler D, et al. Idebenone does not significantly change the pharmacokinetics of amitriptyline, fluvoxamine, and lithium [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1997; 355 Suppl.: R120
58. Herrmann WM. Pharmacokinetic interaction study between idebenone and amitriptyline, given orally, after single and repeated administration of idebenone in healthy volunteers. Takeda (Japan), 1995. Report no.: EC075. (Data on file)
59. Gillis JC, Benfield P, McTavish D. Idebenone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 1994 Aug; 5: 133-52
60. Weyer G, Erzigkeit H, Hadler D, et al. Efficacy and safety of idebenone in the long-term treatment of Alzheimer's disease: a double-blind, placebo controlled multicentre study. Hum Psychopharmacol 1996 Jan-Feb; 11: 53-65
61. Weyer G, Babej-Dölle RM, Hadler D, et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobioloay 1997; 36: 73-82
62. Bergamasco B, Scarzella L, La-Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 1994 May-Jun; 9: 161-8
63. Senin U, Parnetti L, Barbagallo-Sangiorgi G, et al. Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 1992 Nov-Dec; 15: 249-60
64. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984 Nov; 141 (11): 1356-64
65. Herrmann WM, Stephan K. Efficacy and clinical relevance of cognition enhancers. Alz Dis Assoc Disord 1991; 5 Suppl. 1: S7-S12
66. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994 Jun; 4: 510-40
67. Bryson HM, Benfield P, Donepezil. Drugs Aging 1997 Mar; 10: 234-9
68. Lamb H, Faulds D. Metrifonate. Drugs Aging 1997; 11 (6): 490-6
69. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
70. Rogers SL, Perdomo C, Friedhoff LT, et al. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor. E2020 [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 (3): 386-7